SillaJen

SillaJen, Inc. is a biotechnology company with offices in Seoul, South Korea, and the San Francisco financial district. The company focuses on the development and commercialization of oncolytic immunotherapy products using its SOLVE platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer.